VNDA Vanda Pharmaceuticals Inc.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Latest News

1. 02 April 2020 Vanda Pharmaceuticals Announces the Initiation of ODYSSEY, an FDA Approved Clinical Study of Tradipitant in Hospitalized Patients with Severe COVID-19 Pneumonia

   WASHINGTON, April 2, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda") (NASDAQ:VNDA) today announced the initiation of clinical study, ODYSSEY VLY-686-3501, in hospitalized patients with COVID-19. The

2. 27 February 2020 Vanda Pharmaceuticals Announces Participation at March 2020 Investor Conferences

   WASHINGTON, Feb. 27, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA), today announced that it will participate at the following upcoming investor conferences in March 2020: The Cowen and Company

3. 25 February 2020 Vanda Reports results from the EPIONE study of Tradipitant in the treatment of Pruritus in Atopic Dermatitis

   WASHINGTON, Feb. 25, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced results from a Phase III clinical trial (EPIONE) of tradipitant for the treatment of pruritus in atopic

4. 25 February 2020 Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results

   WASHINGTON, Feb. 25, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the fourth quarter and full year ended December 31, 2019. "We had

5. 19 February 2020 Vanda Pharmaceuticals Appoints Stephen Ray Mitchell to Board of Directors

   WASHINGTON, Feb. 19, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) announces the appointment of Stephen Ray Mitchell, M.D. to its Board of Directors. "Ray is a highly respected leader in

6. 18 February 2020 Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results on February 25, 2020

   WASHINGTON, Feb. 18, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the fourth quarter and full year 2019 on Tuesday, February 25, 2020, after the market

7. 31 January 2020 Vanda Pharmaceuticals Comments on Court Ruling

   WASHINGTON, Jan. 31, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) makes the following statement regarding U.S. District Court case 19-cv-30; U.S. Food and Drug Administration (FDA) v. Vanda, in

8. 13 January 2020 Vanda Pharmaceuticals Wins Key U.S. Supreme Court Patent Ruling on Fanapt®

   WASHINGTON, Jan. 13, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) announced today that the U.S. Supreme Court has denied the petition for a writ of certiorari filed by West-Ward Pharmaceuticals

9. 12 December 2019 Mihael H. Polymeropoulos, MD, President and CEO of Vanda Pharmaceuticals Inc., to Receive The Physicians Committee for Responsible Medicine Trailblazer Award

   WASHINGTON, Dec. 12, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) announced today that The Physicians Committee for Responsible Medicine, a nonprofit with more than 12,000 doctor members, will

10. 18 November 2019 Vanda Pharmaceuticals Announces Participation at November 2019 Investor Conferences

    WASHINGTON, Nov. 18, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that it will participate at the following upcoming investor conferences in November 2019: The Stifel 2019

11. 06 November 2019 Vanda Pharmaceuticals Reports Third Quarter 2019 Financial Results

    WASHINGTON, Nov. 6, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended September 30, 2019. "These results affirm

12. 30 October 2019 Vanda Pharmaceuticals to Announce Third Quarter 2019 Financial Results on November 6, 2019

    WASHINGTON, Oct. 30, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the third quarter 2019 and provide a general business overview, on Wednesday,

13. 28 October 2019 Vanda Pharmaceuticals Appoints Anne Sempowski Ward to Board of Directors

    WASHINGTON, Oct. 28, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that Anne Sempowski Ward has joined the company's Board of Directors, effective October 28, 2019. Following

14. 11 September 2019 Vanda Pharmaceuticals Applauds the EPA's Landmark Commitment to Eliminate Animal Testing and Urges the Food and Drug Administration to End Unnecessary and Scientifically Flawed Animal Toxicity Studies

    WASHINGTON, Sept. 11, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA), a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high